Anti-tumor antibody isotype response can be modified with locally administered immunoadjuvants

In situ vaccination with immunostimulatory compounds is a demonstrated means to treat tumors preclinically. While these therapeutic effects have been attributed to the actions of T cells or innate immune activation, characterisation of the humoral immune response is seldom performed. This study aims...

Descripción completa

Detalles Bibliográficos
Autores principales: Walters, Adam A., Ali, Abrar, Wang, Julie Tzu-Wen, Al-Jamal, Khuloud T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238356/
https://www.ncbi.nlm.nih.gov/pubmed/36417163
http://dx.doi.org/10.1007/s13346-022-01258-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238356/
https://www.ncbi.nlm.nih.gov/pubmed/36417163
http://dx.doi.org/10.1007/s13346-022-01258-8

Ejemplares similares